Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, Bui NB, Pény J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Culine S, et al. Among authors: delva r. Ann Oncol. 2007 May;18(5):917-24. doi: 10.1093/annonc/mdm062. Epub 2007 Mar 9. Ann Oncol. 2007. PMID: 17351252 Free article. Clinical Trial.
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P; Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG). Lotz JP, et al. Among authors: delva r. Ann Oncol. 2005 Mar;16(3):411-8. doi: 10.1093/annonc/mdi087. Epub 2005 Jan 19. Ann Oncol. 2005. PMID: 15659420 Free article. Clinical Trial.
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
Trédan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Trédan O, et al. Among authors: delva r. Ann Oncol. 2007 Feb;18(2):256-62. doi: 10.1093/annonc/mdl400. Epub 2006 Nov 2. Ann Oncol. 2007. PMID: 17082510 Free article.
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Delva R, Sevin E, Négrier S, McKendrick J, Santoro A, Pisa P, Escudier B. Melichar B, et al. Among authors: delva r. Ann Oncol. 2008 Aug;19(8):1470-1476. doi: 10.1093/annonc/mdn161. Epub 2008 Apr 11. Ann Oncol. 2008. PMID: 18408224 Free article. Clinical Trial.
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY. Bidard FC, et al. Among authors: delva r. Ann Oncol. 2010 Sep;21(9):1765-1771. doi: 10.1093/annonc/mdq052. Epub 2010 Mar 16. Ann Oncol. 2010. PMID: 20233745 Free article.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, Priou F, Geoffrois L, Rixe O, Beuzeboc P, Malhaire JP, Culine S, Aubelle MS, Laplanche A. Fizazi K, et al. Among authors: delva r. Eur Urol. 2014 Feb;65(2):381-6. doi: 10.1016/j.eururo.2013.09.004. Epub 2013 Sep 13. Eur Urol. 2014. PMID: 24094847
108 results